DNA-based Therapeutics

Synthetics Biologics

Synthetic Biologics Reports First Quarter 2012 Financial Results

Synthetic Biologics Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported financial results for the three months ended March 31, and summarized operational highlights.

WWJ Newsradio 950–05/15/2012

Synthetics Biologics

Synthetic Biologics Announces Completion Of Enrollment In Trial Of MS Drug

Synthetic Biologics Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and medicines for serious illnesses, announced that patient enrollment has been completed in a Phase II clinical trial evaluating the efficacy and safety of Synthetic Biologics’ proprietary oral formulation of estriol (Trimesta) for the treatment of relapsing-remitting multiple sclerosis.

WWJ Newsradio 950–03/14/2012

HR Notices From February 7

The latest staffing, boardroom and leadership changes at Michigan’s technology-focused companies and institutions

WWJ Newsradio 950–02/07/2012

Follow

Get every new post delivered to your Inbox.

Join 2,066 other followers